SOLV
Strong BuyFull HouseAPPROVESolventum Corporation · Healthcare · United States · $15.5B · Avg Vol: $90M/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Solventum clears the calibrated bar. All three legs are above the floor (Q62 V53 M57) and a buyback retiring 0.53% of shares provides the required corroboration. Nothing adverse is on file: no negative earnings revision and no insider selling. Quality at Q62 is the strongest part of the case.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT SOLVENTUM CORPORATION
Read
Solventum Corporation, a recent spin-off from 3M, develops and manufactures a broad portfolio of healthcare products, including medical surgical solutions, dental technologies, and health information systems. The company leverages its established brand reputation, deep customer relationships, and global distribution network to maintain a significant presence across diverse healthcare markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.1B | 8.2B | 8.3B | 8.3B | 0.8% | 8.3B | 8.2B | 8.5B | 1.2% |
| EPS | 7.78 | 7.79 | 2.77 | 8.94 | 4.7% | 8.18 | 10.45 | 10.58 | 8.8% |
| Shares | 172.7M | 172.7M | 172.8M | 173.5M | +0.5% | 170.2M | — | — | — |
| Debt | — | 8.3B | 8.0B | 5.0B | -22.1% | 5.3B | — | — | — |
| Equity | 11.7B | 11.7B | 3.0B | 5.0B | -24.5% | — | — | — | — |
| Op CF | 1.7B | 1.9B | 1.2B | 369.0M | -39.7% | 209.0M | — | — | — |
| Inv CF | -253.0M | -230.0M | -380.0M | 2.8B | — | — | — | — | — |
| Fin CF | -1.5B | -1.6B | -240.0M | -3.1B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SOLV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SOLV | Solventum Corporation(you) | $15.5B | 83 | Strong Buy |
| ALGN | Align Technology, Inc. | $11.2B | 85 | Strong Buy |
| BAX | Baxter International Inc. | $13.5B | 73 | Buy |
| WST | West Pharmaceutical Services, Inc. | $23.7B | 74 | Buy |
| RMD | ResMed Inc. | $34.7B | 87 | Strong Buy |
| ATR | AptarGroup, Inc. | $8.5B | 74 | Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| MMSI | Merit Medical Systems, Inc. | $5.4B | 82 | Strong Buy |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
| NVST | Envista Holdings Corporation | $4.4B | 85 | Strong Buy |
Peer medians: ROE -31.0% · P/E 25.2x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.